ANNX · Nasdaq · CIK 0001528115

Annexon, Inc.

Annexon, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 25, 2026. Its EDGAR record lists 35 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$206.7M
Form 4 filings on record, past 12 months
35

Company overview

Legal name (as filed)
Annexon, Inc.
Ticker
ANNX
SEC Central Index Key (CIK)
0001528115
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
BRISBANE, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2639 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Annexon, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$130.3MFY2021-$141.9MFY2022-$134.2MFY2023-$138.2MFY2024-$206.7MFY2025
ANNX annual results
ItemFY2021
ended Dec 31, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 31, 2023
FY2024
ended Dec 31, 2024
FY2025
ended Dec 31, 2025
Revenue—————
Net income-$130.3M-$141.9M-$134.2M-$138.2M-$206.7M
Diluted EPS-$3.40-$2.60-$1.77-$1.01-$1.34
Total assets$287.0M$285.1M$297.7M$350.1M$277.6M
Cash and equivalents$74.8M$140.0M$225.1M$49.5M$162.1M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ANNX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 12, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 12, 20268-KResults of operations; Other events· period Aug 12, 2026Document · Index
Apr 27, 2026DEF 14ADefinitive proxy statement· period Jun 11, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Annexon, Inc., by form type:

4 ×148-K ×7SCHEDULE 13G/A ×5144 ×310-Q ×23 ×1SCHEDULE 13G ×1ARS ×1DEFA14A ×1DEF 14A ×1PRE 14A ×1S-3ASR ×1S-8 ×110-K ×1
ANNX recent filings
FiledFormWhat it isOriginal
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026Document · Index
Aug 13, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20263Initial statement of beneficial ownership· period Aug 10, 2026Document · Index
Aug 12, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 12, 20268-KResults of operations; Other events· period Aug 12, 2026Document · Index
Aug 10, 20268-KDirector or officer change; Regulation FD disclosure· period Aug 10, 2026Document · Index
Aug 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 6, 20268-KOther events· period Aug 6, 2026Document · Index
Jul 30, 20268-KMaterial agreement; New financial obligation; Other events· period Jul 30, 2026Document · Index
Jul 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 14, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 12, 20268-KShareholder vote results· period Jun 11, 2026Document · Index
May 29, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 20264Statement of changes in beneficial ownership (insider trade)· period May 11, 2026Document · Index
May 7, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 7, 20268-KResults of operations· period May 7, 2026Document · Index
Apr 27, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 27, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 27, 2026DEF 14ADefinitive proxy statement· period Jun 11, 2026Document · Index
Apr 16, 2026PRE 14APRE 14A· period Jun 11, 2026Document · Index
Apr 14, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026Document · Index
Mar 31, 2026S-3ASRSimplified registration statementDocument · Index
Mar 31, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 30, 20268-KResults of operations· period Mar 30, 2026Document · Index
Mar 26, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 12, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 10, 2026Document · Index
Mar 4, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 2, 2026Document · Index

Insider filing activity

35 Form 4 filings appear in Annexon, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001528115 and XBRL company facts. Annexon, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.